Enhancement of neuronal excitability of the major output neurons of the olfactory bulb via blocking voltage-dependent potassium channel reduces body weight in obese mice (Schwartz et al., 2021)
10.1042/BSR20190099 Biosci
Discover / Fat Loss / Fella / Fella Tirzepatide (GLP-1) Treatment Tirzepatide GLP-1 weight loss medication (22.5% avg
Results vary significantly because of genetics, lifestyle, and the quality of the supplement used
Cagrisema is Novo's next-generation combination therapy that pairs the GLP-1 receptor agonist semaglutide with the amylin analogue cagrilintide, and is considered central to the company's efforts to maintain its lead in the fast-growing obesity drug market
Body weight and metabolic health: People with higher body weight, insulin resistance, or prediabetes may need higher doses to see benefits, while others do well on lower doses